Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Gene therapy in dogs shows hope for muscular dystrophy
Labrador
In the study, dogs - which have a similar body size to that of a diseased boy - were injected with the disease when they were two to three months old.

Researchers on the cusp of having a treatment for the disease

A team of researchers have successfully treated dogs with muscular dystrophy using gene therapy. The treatment could pave the the way for clinical trials in humans within the next few years.

The study, published in the journal Human Molecular Genetics, demonstrates for the first time that a common virus can deliver the microgene, which protects against the virus, to all muscles in that of diseased dog.

Muscular dystrophy affects around 250,000 people in the USA and occurs when damaged muscle tissue is replaced with fibrous, fatty or bony tissue and loses function.

Patients with the disease have a gene mutation that disrupts the production of a protein known as 'dystrophin". This is one of the largest genes in the human body and its absence can eventually lead to muscle cell degeneration and death.

Study leader Dongsheg Duan from the University of Missouri explains: “Due to its size, it is impossible to deliver the entire gene with a gene therapy vector, which is the vehicle that carries the therapeutic gene to the correct site in the body.

“Through previous research, we were able to develop a miniature version of this gene called a microgene. This minimised dystrophin protected all muscles in the body of diseased mice.”

In the study, dogs - which have a similar body size to that of a diseased boy - were injected with the disease when they were two to three months old and just starting to show signs of muscular dystrophy.  The dogs are now six to seven months old and continue to develop normally.

“The virus we are using is one of the most common viruses; it is also a virus that produces no symptoms in the human body, making this a safe way to spread the dystrophin gene throughout the body,” added Duan.

“These dogs develop muscular dystrophy naturally in a similar manner as humans. It’s important to treat DMD early before the disease does a lot of damage as this therapy has the greatest impact at the early stages in life.”

Margaret Proctor Mulligan from the University of Missouri's School of Medicine said: “This discovery took our research team more than 10 years, but we believe we are on the cusp of having a treatment for the disease.”

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
NSA webinar explores sheep tailing and castration

The National Sheep Association (NSA) is to host a free webinar on the castration and tail docking of lambs.

The webinar, 'Understanding the tailing and castration consultation: A guide for sheep farmers', will be hosted online on Monday, 2 March 2026 at 7.30pm.

It comes during a government consultation into the methods used for these procedures. Farmers are encouraged to engage before the consultation period closes on Monday, 9 March 2026.

The webinar offers clear and actionable guidance to support farmers to contribute meaningfully to the consultation and prepare for potential changes.

On the panel will be former SVS president Kate Hovers, farmer and vet Ann Van Eetvelt and SRUC professor in Animal Health and Veterinary Sciences Cathy Dwyer. Each panel member will utilise their own specialism and expertise to evaluate risks and outcomes to sheep farming.

Find out more about the webinar on the NSA website.